Show simple item record

dc.contributor.authorVolpato, Milene
dc.contributor.authorCummings, Michele
dc.contributor.authorShaaban, Abeer M
dc.contributor.authorAbderrahman, Balkees
dc.contributor.authorHull, Mark A
dc.contributor.authorMaximov, Philipp Y.
dc.contributor.authorBroom, Bradley M.
dc.contributor.authorHoppe, Reiner
dc.contributor.authorFan, Ping
dc.contributor.authorBrauch, Hiltrud
dc.contributor.authorJordan, V Craig
dc.contributor.authorSpeirs, Valerie
dc.date.accessioned2021-03-23T20:21:01Z
dc.date.available2021-03-23T20:21:01Z
dc.date.issued2020-10-30
dc.identifier.citationVolpato , M , Cummings , M , Shaaban , A M , Abderrahman , B , Hull , M A , Maximov , P Y , Broom , B M , Hoppe , R , Fan , P , Brauch , H , Jordan , V C & Speirs , V 2020 , ' Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer ' , Exploration of Targeted Anti-tumor Therapy , vol. 1 , pp. 355-371 . https://doi.org/10.37349/etat.2020.00021en
dc.identifier.issn2692-3114
dc.identifier.otherPURE: 178239322
dc.identifier.otherPURE UUID: fcba0d40-4b7d-4bc7-963b-d7f01fd940bc
dc.identifier.otherORCID: /0000-0002-0602-4666/work/82658896
dc.identifier.otherPubMed: 33210098
dc.identifier.urihttps://hdl.handle.net/2164/16111
dc.descriptionAcknowledgments We thank Werbena Hamilton-Burke, Loaie Maraqa and Mark Peter for providing clinical data on the breast tumours which populated the TMAs used in this study. Funding: This work was supported in part by Cancer Research UK grant C13432/A9047; Yorkshire Cancer Research grant L314; the Robert Bosch Foundation, Stuttgart, Germany; the NIH; MD Anderson’s Cancer Center support grant CA016672; the George and Barbara Bush Foundation for Innovative Cancer Research; and the Dallas/Fort Worth Living Legend Chair of Cancer Research. The study sponsor(s) played no part in the study design; in the collection, analysis and interpretation of the data; in the writing of the report; and in the decision to submit the paper for publication.en
dc.format.extent17
dc.language.isoeng
dc.relation.ispartofExploration of Targeted Anti-tumor Therapyen
dc.rightsThis is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectBreast canceren
dc.subjectendocrine resistanceen
dc.subject15-hydroxyprostaglandin dehydrogenaseen
dc.subjectimmunohistochemistryen
dc.subjectsurvivalen
dc.subjectR Medicineen
dc.subjectCancer Research UKen
dc.subjectC13432/A9047en
dc.subjectSupplementary Dataen
dc.subject.lccRen
dc.titleDownregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast canceren
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Clinical Medicineen
dc.contributor.institutionUniversity of Aberdeen.Institute of Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.37349/etat.2020.00021


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record